OS Therapies (NYSEAMERICAN:OSTX) Receives “Buy” Rating from D. Boral Capital

OS Therapies (NYSEAMERICAN:OSTX)‘s stock had its “buy” rating reaffirmed by equities research analysts at D. Boral Capital in a research note issued to investors on Friday,Benzinga reports. They presently have a $20.00 target price on the stock.

Other equities analysts also recently issued research reports about the stock. Zacks Research raised shares of OS Therapies from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Lake Street Capital cut their target price on OS Therapies from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, OS Therapies presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.33.

OS Therapies Trading Up 3.0%

OSTX traded up $0.06 on Friday, reaching $1.88. The stock had a trading volume of 345,311 shares, compared to its average volume of 623,976. The company has a market capitalization of $66.02 million, a price-to-earnings ratio of -2.29 and a beta of -4.02. OS Therapies has a fifty-two week low of $1.12 and a fifty-two week high of $7.00. The firm has a 50-day moving average of $1.86 and a 200-day moving average of $1.89.

OS Therapies (NYSEAMERICAN:OSTX) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.21) earnings per share for the quarter. Sell-side analysts anticipate that OS Therapies will post -0.64 EPS for the current fiscal year.

Institutional Investors Weigh In On OS Therapies

Several large investors have recently added to or reduced their stakes in the company. Susquehanna International Group LLP bought a new position in OS Therapies during the third quarter worth about $29,000. Mercer Global Advisors Inc. ADV bought a new stake in shares of OS Therapies in the third quarter valued at approximately $40,000. Ground Swell Capital LLC purchased a new stake in shares of OS Therapies during the 3rd quarter valued at approximately $40,000. CM Management LLC boosted its holdings in OS Therapies by 6.7% in the 3rd quarter. CM Management LLC now owns 400,000 shares of the company’s stock worth $784,000 after buying an additional 25,000 shares during the period. Finally, Bridgeway Capital Management LLC purchased a new position in OS Therapies in the 2nd quarter valued at approximately $47,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.